BusinessModerna Lifts 2026 Revenue Outlook on Newer Vaccine Demand
Moderna raises its full-year 2026 revenue growth guidance to between 15% and 25%, citing accelerating commercial traction across its newer vaccine portfolio.
Arthur Pendelton•
1 views